The new multi-functional facility will initially produce decellurised porcine tissue for the treatment of orthopaedic sports injuries, including ligament repair and meniscus replacement.

According to the company, the applications for orthopaedic sports injuries are currently undergoing clinical trials within the European Union.

The porcine dermis derived application SurgiPure XD recently secured 510(k) clearance from the US Food and Drug Administration (FDA) to repair hernias or body wall defects.

SurgiPure XD will also be manufactured at the new facility.

Tissue Regenix UK operations director Tony Hewitt said: "The facility provides us with the space and capacity we need as we progress the commercialisation of our products.

"Additionally, having the entire UK operations team based at the same site will lead to synergies across our business, allowing us to bring therapies to market more quickly than ever before."

Tissue Regenix is engaged in the commercialization of dCELL technology, which was developed by scientists from the University of Leeds.

The dCELL process uses DNA and cellular material from biological materials such as porcine or human tissue to regenerate healthy tissue in injured patients.

It can be used in the clinical applications, including wound care, sports injuries and heart valve replacement.

Currently, the dCELL technology is being used in the treatment of chronic and acute wounds via DermaPure, specifically addressing the wounds that caused as a side effect of diabetes.

Image: Tissue Regenix UK operations director Tony Hewitt, CEO Antony Odel, chairman John Samuel at the official opening of new manufacturing facility. Photo: courtesy of Business Wire.